![]() He declined to name specific companies but said, "Anyone who sells a noninvasive prenatal test is doing this, so it's pretty easy to compile a list." "I don't see any more lawsuits on the horizon right now, but there are another dozen or so infringers - smaller companies that we're in negotiations with," Desmarais said. Ravgen referred questions to its lead counsel, John Desmarais of Desmarais LLP, who said in an interview his clients hope to reach licensing agreements that could avoid more court cases. 7,332,277 and 7,727,720, which are assigned to Ravgen, provide the basis for its lawsuits, and are under review by the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office. Whether Ravgen can extend its wins depends, in part, on its ability to fend off the challenges to the validity of US Patent Nos. Meanwhile lawsuits are pending against five other firms and negotiations continue with even more as it tries to secure royalties over commonly used methods to identify abnormalities in fetal cell-free DNA contained within a maternal blood sample. So far, the small Maryland-based firm has scored one major court win and reached two settlements. ![]() NEW YORK - In what is shaping up to be a David versus Goliath story, Ravgen is taking on some of the biggest names in the noninvasive prenatal testing space by taking them to court for alleged patent infringement. Advances in Clinical Genomics Profiling. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |